In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claim 4 without prejudice or disclaimer.

Please amend pending claims 1 and 5 as noted below.

Pending Claims

1. (Currently Amended) A method of inducing an antigen specific immune response in a subject, comprising:

administering to the subject in order to induce an antigen specific immune response an antigen and a combination of adjuvants, wherein the combination of adjuvants includes at least one oligonucleotide containing at least one unmethylated CpG dinucleotide and at least one non-nucleic acid adjuvant, wherein the non-nucleic acid adjuvant is a non-saponin immune stimulating adjuvant, ~~and~~ wherein the combination of adjuvants is administered in an effective amount for inducing a synergistic adjuvant response[.], and wherein the oligonucleotide is 8-100 nucleotides in length and has at least one phosphate backbone modification.

2. (Withdrawn) The method of claim 1, wherein the non-nucleic acid adjuvant is an adjuvant that creates a depo effect.

3. (Withdrawn) The method of claim 2, wherein the adjuvant that creates a depo effect is selected from the group consisting of alum, emulsion-based formulations, mineral oil, non-mineral oil, water-in-oil emulsions, oil-in-water emulsions, Seppic ISA series of Montanide adjuvants, MF-59 and PROVAX

4. (Cancelled)

5. (Currently Amended) The method of claim [[4]] 1, wherein the non-saponin immune stimulating adjuvant is selected from the group consisting of ~~saponins~~, PCPP polymer, derivatives of lipopolysaccharides, MPL, MDP, t-MDP, OM-174 and *Leishmania* elongation factor.

6. (Withdrawn) The method of claim 1, wherein the non-nucleic acid adjuvant is an adjuvant that creates a depo effect and stimulates the immune system.

7. (Withdrawn) The method of claim 7, where the adjuvant that creates a depo effect and stimulates the immune system is selected from the group consisting of ISCOMS, SB-AS2, SB-AS4, noniconic block copolymers, and SAF (Syntex Adjuvant Formulation).

8. (Original) The method of claim 1, wherein the combination of adjuvants is administered with a priming dose of antigen.

9. (Original) The method of claim 1, wherein the combination of adjuvants is administered with a boost dose of antigen.

10. (Original) The method of claim 8, wherein the subject is administered a boost dose of antigen and oligonucleotide containing at least one unmethylated CpG dinucleotide after the priming dose.

11. (Original) The method of claim 9, wherein the subject is administered a priming dose of antigen and oligonucleotide containing at least one unmethylated CpG dinucleotide before the boost dose.

12. (Original) The method of claim 1, wherein the oligonucleotide containing at least one unmethylated CpG dinucleotide has a sequence including at least the following formula:

$$5' X_1 X_2CGX_3 X_4 3'$$

wherein C and G are unmethylated, wherein X_1X_2 and X_3X_4 are nucleotides.

13. (Original) The method of claim 12, wherein the 5' X_1 X_2CGX_3 X_4 3' sequence is a non-palindromic sequence.

14. (Original) The method of claim 12, wherein the CpG-containing oligonucleotide is contained within a plasmid or viral vector.

15. (Withdrawn) The method of claim 12, wherein at least one nucleotide has a phosphate backbone modification.

16. (Withdrawn) The method of claim 15, wherein the oligonucleotide has 8 to 100 nucleotides.

17. (Withdrawn) The method of claim 15, wherein the phosphate backbone modification is a phosphorothioate or phosphorodithioate modification.

18. (Withdrawn) The method of claim 15, wherein the phosphate backbone modification occurs at the 5′ end of the oligonucleotide.

19. (Withdrawn) The method of claim 15, wherein the phosphate backbone modification occurs at the 3′ end of the oligonucleotide.

20. (Original) The method of claim 12, wherein X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA.

21. (Original) The method of claim 12, wherein X_1X_2 are selected from the group consisting of GpA and GpT and X_3X_4 are TpT.

22. (Original) The method of claim 12, wherein X_1X_2 are both purines and X_3X_4 are both pyrimidines.

23. (Original) The method of claim 12, wherein X_2 is a T and X_3 is a pyrimidine.

24. (Original) The method of claim 12, wherein the oligonucleotide is 8 to 40 nucleotides in length.

25. (Original) The method of claim 12, wherein the oligonucleotide is isolated.

26. (Original) The method of claim 12, wherein the oligonucleotide is a synthetic oligonucleotide.

27. (Original) The method of claim 1, wherein the subject is an infant.

28. (Original) The method of claim 1, wherein the antigen is derived from an infectious organism selected from the group consisting of a virus, bacterium, fungus and parasite.

29. (Original) The method of claim 1, wherein the antigen is a tumor antigen.

30. (Original) The method of claim 1, wherein the antigen is an allergen.

31. (Original) The method of claim 1, wherein the antigen is in the form of a crude extract.

32. (Original) The method of claim 1, wherein the antigen is in the form of a purified molecule including a protein or a polysaccharide.

33. (Original) The method of claim 1, wherein the antigen is in the form of a recombinant molecule including a protein, polypeptide, peptide or peptide mimic of a polysaccharide antigen.

34. (Withdrawn) The method of claim 1, wherein the non-nucleic acid adjuvant by itself give a TH2 immune response (e.g., alum) but when used in combination with the CpG oligonucleotide gives a Th1 response.

35. (Original) The method of claim 1, wherein the non-nucleic acid adjuvant by itself gives a Th1 immune response (e.g., MPL) but when used in combination with the CpG oligonucleotide gives a stronger Th1 response.